PKPatricia König

Patricia König

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia König has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Characterization of C-strain “Riems” TAV-epitope escape variants obtained through selective antibody pressure in cell culture

    by Immanuel Leifer, Sandra Blome, Ulrike Blohm, Patricia König, Heike Küster, Bodo Lange, Martin Beer

    Classical swine fever virus (CSFV) C-strain “Riems” escape variants generated under selective antibody pressure with monoclonal antibodies and a peptide-specific antiserum in cell culture were investigated. Candidates with up to three amino acid exchanges in the immunodominant and highly conserved linear TAV-epitope of the E2-glycoprotein, and additional mutations in the envelope proteins ERNS and E1, were characterized both in vitro and in vivo. It was further demonstrated, that intramuscular immunization of weaner pigs with variants selected after a series of passages elicited full protection against lethal CSFV challenge infection. These novel CSFV C-strain variants with exchanges in the TAV-epitope present potential marker vaccine candidates. The DIVA (differentiating infected from vaccinated animals) principle was tested for those variants using commercially available E2 antibody detection ELISA. Moreover, direct virus differentiation is possible using a real-time RT-PCR system specific for the new C-strain virus escape variants or using differential immunofluorescence staining.


  • Innocuousness and safety of classical swine fever marker vaccine candidate CP7_E2alf in non-target and target species

    by Patricia König, Sandra Blome, Claudia Gabriel, Ilona Reimann, Martin Beer


    • 6 June 2003
      • Vol. 116, 183-91

    [Diagnostic markers in the prevention of bovine herpesvirus type 1: possibilities and limitations].

    by Martin Beer, Patricia König, Guido Schielke, Sascha Trapp

    The usage of glycoprotein E (gE)-deleted BHV-1 marker or DIVA (differentiating infected from vaccinated animals) vaccines in combination with the accompanying determination of gE-specific antibodies is one of the basic parts of BHV-1 eradication programs in Germany. Following the adoption of the "Legislation for the protection of cattle holdings from an infection with Bovine Herpesvirus Type 1" in 1997, several million gE-antibody assays were conducted. Up to now, commercially available gE-blocking enzyme linked immunosorbent assays (ELISAs) are the only test systems available for the detection of gE-specific antibodies. However, there are some difficulties to meet the high requirements on their performance. Therefore, role and function of gE in the virus and the host as well as the principle of gE marker assays, the test design and the capability of the mainly used ELISAs are illuminated in this paper. Additionally, suggestions concerning the optimal usage and the correct application of gE-blocking-ELISAs are discussed.


    • 6 June 2003
      • Vol. 116, 208-15

    [Conventional and marked BHV-1 vaccines in Germany: a brief review].

    by Sascha Trapp, Patricia König, Martin Beer

    Since 1997 infections of cattle with bovine herpesvirus type 1 (BHV-1) are regulated by the German government with obligatory measures. Eradication of the virus is based on two different concepts: German federal states with a low BHV-1-seroprevalence comply with a selection concept, that provides deletion of BHV-1-positive cattle and only exceptional vaccination. States with a high BHV-1-prevalence attempt to eradicate the virus using the marker concept. The marker concept is based on the vaccination with glycoprotein E (gE)-deleted marker vaccines and the accompanying serological differentiation between vaccinated and infected animals. This review deals with both, conventional and marked BHV-1 vaccines, that are commercially available in Germany. Efficacy and safety of different inactivated vaccines and modified live vaccines have been evaluated in detail in several international experimental studies and field trials. Results of these studies are briefly reviewed and discussed in this article.